TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today presented initial data from the Phase 1 AMBER trial of TSR-022 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE